What prevents cardioprotective drugs from reaching the market?

Expert Rev Clin Pharmacol. 2018 May;11(5):463-465. doi: 10.1080/17512433.2018.1447924. Epub 2018 Mar 12.

Authors

Fedor Simko^{1

2

3}, Michaela Adamcova⁴

Affiliations

¹ a Institute of Pathophysiology, Faculty of Medicine , Comenius University , Bratislava , Slovak Republic.
² b 3rd Department of Internal Medicine, Faculty of Medicine , Comenius University , Bratislava , Slovak Republic.
³ c Institute of Experimental Endocrinology, BMC , Slovak Academy of Sciences , Bratislava , Slovak Republic.
⁴ d Department of Physiology, Faculty of Medicine in Hradec Kralove , Charles University , Czech Republic.

PMID: 29495886
DOI: 10.1080/17512433.2018.1447924

No abstract available

Keywords: Cardioprotection; cardiovascular drugs; cardiovascular event; clinical trials; market; mortality.

Publication types

Editorial

MeSH terms

Animals
Cardiotonic Agents / pharmacology*
Cardiovascular Diseases / physiopathology
Cardiovascular Diseases / prevention & control*
Drug Approval*
Drug Design
Humans

Substances

Cardiotonic Agents